R&D News | pharmaphorum

News

Lilly to sell generic Humalog insulin at half price

Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand.

News

CHMP okays Sanofi’s Zynquista in type 1 diabetes

Sanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

News

Celgene gets fast FDA review of Revlimid combo in lymphoma

Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan.

News

Signing paperwork with a fountain paperwork. The image has added grain and styling.

M&A flurry continues with $21bn Danaher bid for GE unit

GE Healthcare was supposed to be heading for an initial public offering (IPO) this year, but that looks less likely after a $21.4 billion buyout offer for its biopharma unit from medtech co

News

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP

News

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

Lilly to sell generic Humalog insulin at half price

CHMP okays Sanofi’s Zynquista in type 1 diabetes

Celgene gets fast FDA review of Revlimid combo in lymphoma

M&A flurry continues with $21bn Danaher bid for GE unit

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Novartis licenses lipoprotein-lowering CVD drug

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks